Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic… (NCT00003243) | Clinical Trial Compass
CompletedPhase 1
Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer
United StatesStarted 1998-01
Plain-language summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. White blood cells from donors may be able to kill cancer cells in patients who have hematologic cancer that has recurred following bone marrow transplantation.
PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus infusion of donated white blood cells in treating patients who have hematologic cancer that has recurred after bone marrow transplantation.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Diagnosis of relapsed or persistent acute leukemia, myelodysplasia, aggressive non-Hodgkin's lymphoma (NHL), or chronic myeloid leukemia in transformed phase (accelerated phase or blast crisis) after allogeneic bone marrow transplantation (BMT)
* Aggressive NHL defined as diffuse mixed, diffuse large cell, diffuse small noncleaved cell, and lymphoblastic histologies
* No active acute graft versus host disease (GVHD) or extensive chronic GVHD
PATIENT CHARACTERISTICS:
Age:
* Not specified
Performance status:
* ECOG 0-2
Life expectancy:
* More than 4 weeks
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Not specified
Other:
* No severe psychiatric illness or mental deficiencies
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* See Disease Characteristics
* At least 6 months since prior allogeneic BMT
* No other concurrent interleukin-2
* No other concurrent immunomodulatory medication (e.g., interferon)
Chemotherapy:
* Not specified
Endocrine therapy:
* No concurrent steroids
Radiotherapy:
* Not specified
Surgery:
* Not specified
Other:
* No concurrent immunosuppressive medication (e.g., cyclosporine) for GVHD
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Trial details
NCT IDNCT00003243
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins